Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 31, 2021 in Prostate cancer | 0 comments

In a nutshell

This study compared the safety outcomes between moderately-hypofractionated intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT) in patients with early-stage prostate cancer. The data showed that both treatments were safe and well-tolerated.

Some background

Radiation therapy (RT) is a treatment used for low- or intermediate-risk prostate cancer (PCa). This can include proton beam therapy or intensity-modulated radiation therapy.

Proton beam therapy (PBT) is a type of radiation therapy that uses a beam of special particles, called protons, instead of X-rays to destroy cancer cells. PBT delivers the high-energy more precisely to the cancer cells and less to the surrounding healthy tissues such as the bladder and genitals. Moderately-hypofractionated intensity-modulated radiation therapy (IMRT) is an advanced type of high-precision RT. It uses X-ray beams to target and destroy the prostate tumor. IMRT involves a shorter course of treatment (4-6 weeks) with larger doses of radiation delivered in each treatment. There are very few studies comparing the safety outcomes of the 2 treatments in patients with early-stage PCa.

Methods & findings

This study involved 1850 patients with low- to intermediate-risk PCa. Patients were put into 2 groups. Group 1 included 1282 patients who received IMRT. Group 2 included 568 patients who received PBT. The average follow-up period was 80 months for the IMRT group and 43.9 months for the PBT group.

Overall, 56.6% of all patients did not experience any late genitourinary (GU; genitals and urinary organs) toxic effects. 74.4% of patients did not have any late gastrointestinal (GI) side-effects. No significant differences in the late toxicity were seen between the 2 treatment groups.

The bottom line

This study showed that both IMRT and PBT were safe and resulted in low rates of toxicity in early-stage PCa.

The fine print

The study was conducted at multiple single institutions. Patient-reported quality of life outcome data is missing.

Published By :

International journal of radiation oncology, biology, physics

Date :

Feb 01, 2021

Original Title :

A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity-Modulated Radiation Therapy in Early Stage Prostate Cancer Patients.

click here to get personalized updates